Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of IMRX is 17 and suggests 153% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell